» Articles » PMID: 10348759

Use of Microdilution Panels with and Without Beta-lactamase Inhibitors As a Phenotypic Test for Beta-lactamase Production Among Escherichia Coli, Klebsiella Spp., Enterobacter Spp., Citrobacter Freundii, and Serratia Marcescens

Overview
Specialty Pharmacology
Date 1999 May 29
PMID 10348759
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past decade, a number of new beta-lactamases have appeared in clinical isolates of Enterobacteriaceae that, unlike their predecessors, do not confer beta-lactam resistance that is readily detected in routine antibiotic susceptibility tests. Because optimal methodologies are needed to detect these important new beta-lactamases, a study was designed to evaluate the ability of a panel of various beta-lactam antibiotics tested alone and in combination with beta-lactamase inhibitors to discriminate between the production of extended-spectrum beta-lactamases, AmpC beta-lactamases, high levels of K1 beta-lactamase, and other beta-lactamases in 141 isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens possessing well-characterized beta-lactamases. The microdilution panels studied contained aztreonam, cefpodoxime, ceftazidime, cefotaxime, and ceftriaxone, with and without 1, 2, and 4 microg of clavulanate per ml or 8 microg of sulbactam per ml and cefoxitin and cefotetan with and without 8 microg of sulbactam per ml. The results indicated that a minimum panel of five tests would provide maximum separation of extended-spectrum beta-lactamase high AmpC, high K1, and other beta-lactamase production in Enterobacteriaceae. These included cefpodoxime, cefpodoxime plus 4 microg of clavulanate per ml, ceftazidime, ceftriaxone, and ceftriaxone plus 8 microg of sulbactam per ml. Ceftriaxone plus 2 microg of clavulanate per ml could be substituted for cefpodoxime plus 4 microg of clavulanate per ml without altering the accuracy of the tests. This study indicated that tests with key beta-lactam drugs, alone and in combination with beta-lactamase inhibitors, could provide a convenient approach to the detection of a variety of beta-lactamases in members of the family Enterobacteriaceae.

Citing Articles

Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam.

Kaur J, Mahajan G, Chand K, Sheevani , Chopra S J Clin Diagn Res. 2016; 10(1):DC05-8.

PMID: 26894064 PMC: 4740591. DOI: 10.7860/JCDR/2016/15264.7041.


AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.

Gupta V, Kumarasamy K, Gulati N, Garg R, Krishnan P, Chander J Indian J Med Res. 2012; 136(2):237-41.

PMID: 22960890 PMC: 3461735.


Nosocomial blood stream infection in intensive care units at Assiut University Hospitals (Upper Egypt) with special reference to extended spectrum beta-lactamase producing organisms.

Ahmed S, Daef E, Badary M, Mahmoud M, Abd-Elsayed A BMC Res Notes. 2009; 2:76.

PMID: 19419535 PMC: 2694819. DOI: 10.1186/1756-0500-2-76.


Comparison of Phoenix and VITEK 2 extended-spectrum-beta-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized beta-lactamases.

Thomson K, Cornish N, Hong S, Hemrick K, Herdt C, Moland E J Clin Microbiol. 2007; 45(8):2380-4.

PMID: 17596369 PMC: 1951213. DOI: 10.1128/JCM.00776-07.


Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.

Moland E, Hanson N, Black J, Hossain A, Song W, Thomson K J Clin Microbiol. 2006; 44(9):3318-24.

PMID: 16954267 PMC: 1594717. DOI: 10.1128/JCM.00756-06.


References
1.
Ehrhardt A, Sanders C, Moland E . Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae. Antimicrob Agents Chemother. 1999; 43(3):630-3. PMC: 89171. DOI: 10.1128/AAC.43.3.630. View

2.
Katsanis G, Spargo J, Ferraro M, Sutton L, Jacoby G . Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol. 1994; 32(3):691-6. PMC: 263108. DOI: 10.1128/jcm.32.3.691-696.1994. View

3.
Gazouli M, Tzouvelekis L, Prinarakis E, Miriagou V, Tzelepi E . Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2). Antimicrob Agents Chemother. 1996; 40(7):1736-40. PMC: 163408. DOI: 10.1128/AAC.40.7.1736. View

4.
Vedel G, Belaaouaj A, Gilly L, Labia R, Philippon A, Nevot P . Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors. J Antimicrob Chemother. 1992; 30(4):449-62. DOI: 10.1093/jac/30.4.449. View

5.
Rice L, Eckstein E, Devente J, Shlaes D . Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 1996; 23(1):118-24. DOI: 10.1093/clinids/23.1.118. View